Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy
Jing-Jing Du, Rongling Liu, Lei Chen, Jian Zhang · 2026
Read Rational design of D(+)-biotin-conjugated resorcinol dibenzyl ethers as tumor-targeted PD-L1 inhibitors for precision cancer immunotherapy by Jing-Jing Du, Rongling Liu, Lei Chen, Jian Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582261.txt.
Description
Jing-Jing Du, Rongling Liu, Lei Chen, and Jian Zhang design a tumor-targeted molecule that blocks a key immune checkpoint, in a research paper from 2026. The checkpoint, PD-L1, helps cancers evade immune attack. Their compound links a small blocking molecule to biotin, a vitamin that many tumors pull in eagerly.
The lead compound blocked the PD-1 and PD-L1 interaction at very low doses in lab tests. It bound the target tightly and stayed stable in simulations. In mice with melanoma, it slowed tumor growth more than a standard antibody drug. More killer T cells entered the tumors, and the mice kept their weight. The authors present it as a lead for further development.
Catalog record
| CREATOR | Jing-Jing Du, Rongling Liu, Lei Chen, Jian Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |